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I. ABSTRACT

SILENT CEREBRAL INFARCTION IN PATIENTS WITH NONRHEUMATIC
ATRIAL FIBRILLATION. Mark L. Meyer and Michael D. Ezekowitz, Section
of Cardiology, Department of Internal Medicine, Yale University School of
Medicine, New Haven, Connecticut, and Kenneth E. James, Department of
Veterans Affairs Cooperative Studies Program Coordinating Center, Palo
Alto, California.

Silent cerebral infarction has recently emerged as an entity found in
subgroups of patients with a history of symptomatic stroke, TIA, carotid
disease, or atrial fibrillation.

To examine more closely the prevalence of

silent cerebral infarction among patients with atrial fibrillation, data from
cerebral CT scans from the Stroke Prevention in Nonrheumatic Atrial
Fibrillation (SPINAF) study were analyzed. During the SPINAF study, which
evaluated

warfarin

for

the

prevention

of

stroke

in

patients

with

nonrheumatic atrial fibrillation and no clinical evidence of previous stroke,
non-contrast CT scans of the head were performed on all patients at entry, at
the time of any neurologic event, and at termination of follow-up for those
who completed the study without an event. These scans were evaluated by a
central committee of six neurologists and neuroradiologists, and the location,
size, and vascular territory of all lucent lesions were archived.
determined the following:

We then

The prevalence of silent infarction in patients

with atrial fibrillation, risk factors associated with silent infarction, the effect
of warfarin therapy on the development of silent infarction, and the
relationship between silent infarction and the development of symptomatic
stroke.

Of 516 evaluable scans, 77 (14.9 percent) had evidence of silent cerebral
infarction.

A univariate comparison found age (p=0.011), a history of

hypertension (p=0.003), active angina (p=0.012), and mean systolic blood
pressure (p<0.0001) to be independently predictive of silent infarction.

The

incidence rates of silent infarction were 1.77 and 0.77 percent per year for the
warfarin and placebo treatment groups, respectively.

Silent infarction was

found to be suggestive of the development of symptomatic stroke (p=0.051),
while warfarin did not appear to influence the development of silent
infarction.
We conclude that the prevalence of silent cerebral infarction among
neurologically normal patients with atrial fibrillation was 14.9 percent, and
that age, a history of hypertension, active angina, and mean systolic blood
pressure were predictive of silent infarction.

In addition, silent cerebral

infarction was a marker of increased risk for the development of symptomatic
stroke.

Finally, we suggest a new mechanism for silent infarction, namely

hypertensive small vessel disease, and discuss the clinical implications of this
mechanism.
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II. INTRODUCTION

A. Cerebrovascular Disease
1. Magnitude of the Problem and Definition
Cerebrovascular disease is the third leading cause of death in
developed countries, preceded only by heart disease and cancer.

Its overall

prevalence has been estimated at 794 per 100,000 population, with more than
five percent of the population over 65 years of age affected.

In the United

States, current estimates indicate that in excess of 400,000 patients per year are
discharged from hospitals following a stroke.

The economic burden created

by the hospitalization and subsequent treatment of stroke victims is one of
the most onerous in health care today. 1
A stroke is defined as an acute neurologic injury resulting from one of
a number of pathologic processes.

Clinically, strokes may vary in severity

along a spectrum spanning silent strokes, detected only on neuroradiologic
examination, and transient ischemic attacks (TIAs) which refer to any sudden
focal neurologic deficit which resolves within 24 hours, to catastrophic events
resulting in severe incapacitation or even sudden death.

These clinical

manifestations result from the interruption of the continuous supply of
oxygenated blood which ensures normal brain function.

Indeed animal

experiments reveal that total cessation of blood flow results in irreversible
cerebral infarction within three minutes. 1
The categories of stroke may be broadly characterized as ischemic and
hemorrhagic, with ischemic strokes being the more common.

The risk

factors for both categories include cardiac disease, previous stroke, age, and
hypertension.

It has been acknowledged that hypertension is the strongest

risk factor for stroke, and thus the advent of antihypertensive therapy has

2
been the principal factor accounting for the dramatic decline of stroke-related
mortality since 1975.

Nevertheless, there are numerous other factors

associated with cerebrovascular disease whose prominence continues to be
uncovered by ongoing studies of the pathogenesis and prevention of stroke.
2. .Etiology
The causes of ischemic cerebrovascular disease (the category with
which is the subject of this inquiry) may be divided into non-cardiac and
cardiac factors (Tables 1 and 2). Among the important non-cardiac causes are
atherosclerosis, arteritis, hematologic disorders, cerebral vasospasm, and
reversible cerebral vasoconstriction.

Additionally, certain conditions show

associations of varying significance with ischemic cerebrovascular disease,
including hypercoagulable states secondary to systemic disease, carcinoma,
eclampsia, use of oral contraceptives, and lupus. 1
The cardiac causes of ischemic cerebrovascular disease are multifold.
However, these multiple etiologies share the common mechanism of
systemic embolization (Table 2).3 One documented source of emboli arises as
a result of the "paradoxical complications" of cardiac manipulation, including
both cardiac catheterization and cardiac surgery. Emboli from the heart lodge
in the middle cerebral artery or one of its branches 80 percent of the time, in
the posterior cerebral artery or its branches 11 percent of the time, with the
remainder finding their way to the vertebral or basilar arteries. 1 As indicated
in Table 2, the left ventricle is an important source of systemic embolization,
resulting from transmural myocardial infarction (anterior or inferior), left
ventricular aneurysm, cardiomyopathy (left ventricular dysfunction), and less
commonly, ventricular tumors.

Cardiac valvulopathy is another important

source of systemic emboli, resulting from endocarditis (infective and
noninfective), prosthetic valve dysfunction, and rheumatic heart disease.

3

Additionally, stenosis and insufficiency of both the mitral and aortic valves,
as well as mitral valve prolapse, contribute to the pathologic armamentarium
of systemic emboli.3
The most important source of systemic emboli is thrombus in the left
atrium.

Less commonly, atrial tumors

(myxomas)

and

atrial septal

aneurysms may cause strokes. Most commonly, left atrial thrombi occur as a
consequence of atrial fibrillation, a condition resulting from multiple causes,
listed in Table 3.3

Of note, while other sources of emboli in patients with

atrial fibrillation have been

postulated,^

it is widely assumed that the left

atrium is the source of emboli in most of these

B.

patients.3

Atrial Fibrillation as a Cause of Stroke
1. Significance of the Arrhythmia
The importance of atrial fibrillation as a source of systemic emboli

must not be underestimated. To begin with, the incidence of atrial fibrillation
in patients over 60 years of age without valvular disease is estimated to be 2-4
percent per

year.3

The prevalence of atrial fibrillation increases with age;

indeed, the prevalence in patients greater than seventy years of age is
estimated to be as high as nine

percent.3

Furthermore, patients with

nonvalvular atrial fibrillation have a five-fold excess of stroke relative to
comparable patients in sinus
of approximately 5

rhythm,!'6-8 corresponding to a yearly incidence

percent.6

It has been shown that up to 35 percent of all

patients with nonvalvular atrial fibrillation eventually suffer cerebral
infarction.6

In addition, in a study of the four main cardiovascular

conditions predisposing to stroke (hypertension, coronary heart disease,
cardiac failure, and atrial fibrillation), the attributable risk of atrial fibrillation
increased significantly with age (from 1.5 percent in the 50-59 age group, to
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23.5 percent in the 80-89 age group), while the other conditions were either
unaffected by or decreased in significance with age.2

Importantly, atrial

fibrillation exerts a significant impact on the risk of stroke which is
independent of associated cardiac abnormalities (hypertension, cardiac failure,
coronary heart disease), although it has also been shown to increase the stroke
risk in the overt presence of these conditions.2

A recent study of 154

consecutive anterior circulation stroke patients with atrial fibrillation who
were evaluated for alternative mechanisms of the stroke with carotid
angiography or noninvasive cardiac testing found atrial fibrillation to be the
sole stroke mechanism in 76 percent of these patients.^
Given the significant impact of atrial fibrillation on stroke, five recent
clinical trials have evaluated the use of aspirin and or warfarin to prevent
stroke in patients with atrial fibrillation.6-7,10-12 institution of preventative
measures as soon as atrial fibrillation is diagnosed is important for two
reasons. First, embolic events often occur shortly after atrial fibrillation first
develops. One study reported that 33 percent of emboli occurred within one
month and 66 percent within twelve months after its onset.3 And second, in
many cases, the initial stroke causes severe disability. 1 What follows is a brief
summary of the results of the five atrial fibrillation studies.
2.

Clinical Trials Evaluating Warfarin and Aspirin as a Means of

Stroke Prevention^
The five atrial fibrillation trials were the Atrial Fibrillation, Aspirin,
Anticoagulation

Study

from

Copenhagen

(AFASAK),10 the Stroke

Prevention in Atrial Fibrillation Study (SPAF),6/13 the Boston Area
Anticoagulation Trial for Atrial Fibrillation (BAATAF),H the Canadian
Atrial

Fibrillation

Anticoagulation

Study

(CAFA),-7 and the Stroke

Prevention in Nonrheumatic Atrial Fibrillation Study (SPINAF).!^ Each trial

5
evaluated the efficacy of warfarin, generally with the goal of a low
prothrombin-time ratio (1.2-1.5).

In addition, the AFASAK and SPAF trials

evaluated aspirin as an alternative therapy (using 75 and 325 mg once per day,
respectively).

CAFA and SPINAF excluded aspirin and nonsteroidal anti¬

inflammatory agents, while the BAATAF study allowed the patients in the
placebo group to use aspirin (325 mg once per day).

All five studies were

placebo-controlled, randomized studies which were terminated early.

The

BAATAF and AFASAK studies were not blinded, the SPAF study was doubleblinded for aspirin but unblinded for warfarin, while the SPINAF and CAFA
trials were double-blinded for warfarin.
thereof as its primary endpoint.

Each trial used stroke or a variant

Finally, in the SPINAF and AFASAK

studies, intermittent atrial fibrillation was an exclusion.
The main result of all five trials was the demonstration of the efficacy
of warfarin in protecting against systemic embolization, both in chronic (all
five) and intermittent (CAFA, SPAF, BAATAF) atrial fibrillation.

In the

three unblinded studies (CAFA, SPAF, BAATAF), reduction in cerebral
vascular events ranged from 67 to 86 percent.

The double-blinded SPINAF

trial had a 79 percent risk reduction of cerebral infarction, while the CAFA
study, though terminated early, revealed a non-statistically significant trend
in favor of warfarin.

In addition, the SPINAF study indicated that warfarin

protection may apply to recurrent cerebral infarction, as well as to the
prevention of initial events. The risk of major hemorrhage secondary to lowintensity anticoagulation was similar for warfarin and placebo.7,10-11,13 The
SPINAF study demonstrated a higher incidence of minor hemorrhage in the
warfarin group.
The benefit of aspirin remains controversial.

The AFASAK study

revealed no benefit of aspirin versus placebo, while the SPAF trial noted a
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benefit of aspirin only in patients less than 75 years of age.

In the SPAF

population overall, however, the incidence of ischemic stroke and systemic
embolization for aspirin-treated patients was 3.6 percent per year, versus 0.9
percent per year for cerebral infarction alone in the warfarin-treated SPINAF
patients. A recent "treatment-received" analysis of the BAATAF study found
no support for the efficacy of aspirin in preventing stroke in patients with
atrial fibrillation.14 This study revealed the unadjusted rate of stroke among
patients in the aspirin group to be 3.9 percent, which was approximately 9
times the rate among patients taking warfarin. And even after controlling for
the imbalance resulting from the non-randomization of patients within the
aspirin group with respect to coexisting risk factors, this study still
demonstrated a 7-fold increase in stroke among the aspirin versus warfarin
patients.
Finally, despite these five trials, the subgroups of atrial fibrillation
patients at high risk for stroke prevention remain somewhat elusive.

The

BAATAF study identified age as a positive risk factor, and both the BAATAF
and SPINAF studies found active angina to positively influence the risk of
stroke.

There was controversy among the studies regarding the effect of

mitral annular calcification, recent history of cardiac failure, left atrial size,
decreased left ventricular function, and recent onset of arrhythmia.H/13 One
group identified by all five trials to be at relatively low risk for embolic events
includes those patients with "lone atrial fibrillation," defined as atrial
fibrillation without concomitant structural heart disease, hypertension, or
diabetes.

This group constitutes approximately 2 to 4 percent of the

population with chronic atrial fibrillation, and their risk of embolization is
estimated at 1.3-1.4 percent per year.3

7
The overall recommendation which emerges from these five trials is
for low-intensity anticoagulation with warfarin in all patients with nonvalvular atrial fibrillation who can tolerate this therapy, with the exception of
the subgroup of lone atrial fibrillators who do not require anticoagulation, but
who may benefit from

3 As discussed above, the value of aspirin as a

aspirin.

preventative measure is not resolved, but clearly any such benefit is
substantially less than that afforded by therapeutic anticoagulation.

Finally,

the optimal dose for warfarin is the maintenance of a prothrombin-time ratio
of 1.2 to 1.5, corresponding to an International Normalized Ratio (INR) of 1.38
to 2.5;3/12-13

however, the lowest effective dose of warfarin has yet to be

defined. If aspirin is to be used, the appropriate dose is thought to be 325 mg
once per

day.3

C. Silent Cerebral Infarction
1.

Definition

The preceding discussion of atrial fibrillation and stroke focused on
prevention of clinically apparent events.

However, as discussed earlier,

strokes may vary in their severity from clinically silent to catastrophically
incapacitating. Some authors have indeed suggested that "silent stroke" is an
oxymoron, for stroke is by definition a symptomatic event, and have instead
offered "silent infarction" as a better term.15 Either way, the important point
is that an entity exists, variously designated silent stroke, silent cerebral
ischemia, or silent or asymptomatic cerebral infarction, which refers to
computerized tomographic (CT) evidence of cerebral infarction (hypodense
lesions,

or

lucencies)

phenomenon

has

without

entered

the

a

prior

history

literature

of

relatively

stroke.!6
recently,

As this
limited

information about this important finding exists, and in fact, the prevalence in

8
the general population has not to date been documented.

Nevertheless,

silent cerebral infarction among certain subgroups has been examined.

The

following section will discuss the information about silent stroke in patients
with clinically evident stroke, with a history of TIA, and with carotid disease
(Table 4).

Following this analysis, the important and still-emerging

relationship between silent cerebral infarction and atrial fibrillation will be
addressed (Table 5).
2. Silent Cerebral Infarction in Patients with Symptomatic Stroke or
TIA
The prevalence of silent stroke

in patients

who present with

symptomatic stroke has been investigated in two studies.

One of these was

conducted by the Framingham investigators,^6 and the other utilized the
National Institute of Neurological and Communicative Disorders and Stroke
(NINCDS) data bank.l'7 The Framingham study focused on 124 patients with
initial neurologic events who underwent CT scanning at the time of the
initial event. This study found that 13 out of the 124 patients, or 10.5 percent,
had evidence of silent infarction. Fifty percent of the lesions in these patients
represented lacunar strokes in the basal ganglia and internal capsule areas,
while the other fifty percent were small cortical infarcts.

The authors

postulated that these infarcts were silent either due to their size or their
location, or because the defect produced was not noticed by the patient (e.g.,
quadrantanopia).

Among patients with silent infarction, hypertension (76.9

percent of these patients), smoking (53.8 percent), and atrial fibrillation (23.1
percent) were found to be risk factors, but only glucose intolerance was
statistically more common in the silent stroke group relative to the
remaining 111 symptomatic stroke patients without evidence of silent
infarction.

9
The interrogation of the NINCDS data revealed the prevalence of
silent stroke to be 11 percent (135 out of 1203 patients),! ^ which is almost
identical to that obtained from the Framingham data.

Of note, however,

"silent stroke" in this study consisted both of asymptomatic (74.9 percent) and
unreported but clinically evident lesions (25.1 percent) unrelated to the initial
reported
definition.

(presenting)

thus

expanding

However, the majority of patients

Framingham definition.
identified:

stroke event,

the

Framingham

(74.9 percent)

fit the

As in Framingham, two geographic patterns were

one of small, deep lesions, and the other consisting of large,

superficial lesions.

This study concluded, in accord with Framingham, that

the silence of the infarcts was due to their small size and location in the depth
of the hemisphere (while noting that the unreported but clinically evident
group often had visual defects, e.g. hemianopia or more commonly
quadrantanopia which went unnoticed).

There was no difference in the

incidences of hypertension, prior myocardial infarction, atrial fibrillation,
diabetes mellitus, or prior TIA in patients with silent infarctions relative to
the remainder of the stroke data bank patients.
as a positive risk factor for silent infarction.

However, age was identified
Thus it seems from these two

studies that among patients who develop symptomatic stroke which brings
them to the attention of a physician and thence to the CT scanner, silent
cerebral infarction is not an uncommon finding.

The risk factors which

isolate patients within this group as more likely to have evidence of silent
infarction have not been clearly defined, with only age and glucose
intolerance as possible independent variables.

At issue, however, are risk

factors which distinguish among stroke patients.

Thus hypertension, atrial

fibrillation and coronary disease are not ruled out as independent risk factors
for silent infarction.

Indeed, a recent study by a Japanese investigative team

has suggested that in addition to age, hypertension is an independent risk
factor for silent infarction in patients with coronary heart

disease.! 9

Another study of silent infarction analyzed data generated by the Dutch
TIA study. 19 The cohort in this study consisted of 2329 patients with a history
of TLA or minor ischemic stroke. Among this group, 13 percent had evidence
of silent cerebral infarction;

79 percent of these lesions were lacunar, 14

percent were cortical, and 7 percent were located in the border zone.

Age

greater than 65, hypertension, and current cigarette smoking were identified
as risk factors for silent stroke in these patients, consistent with the
Framingham and NINCDS results. 16-17

Importantly, atrial fibrillation was

an exclusion criterion for the Dutch trial. In addition, both this study and the
NINCDS analysis found that silent stroke was more likely to be accompanied
by symptomatic lacunar as opposed to symptomatic cortical infarct, when a
patient had both silent and symptomatic infarction. 17,19

Finally, the

investigators in this study hypothesized that "because only the sites of silent
stroke infarcts differed slightly from those of symptomatic infarcts, and the
frequency of vascular risk factors was similar to that of symptomatic infarcts,
silent stroke may have the same bearing on future risk as known prior
stroke."!'7

Of note, this was only an hypothesis, not a demonstrated

conclusion of the study.
3. Silent Cerebral Infarction and Carotid Disease
Next, a number of investigators have examined the link between
carotid disease and silent infarction.
relationship to be unresolved.
thromboendarterectomy

In short, these studies show the

In one study, 96 patients admitted for carotid

underwent preoperative

CT

scanning,

which

revealed 17 patients, or 18 percent, to have silent infarctions, predominantly
20 The incidence of hemodynamically significant carotid stenosis (14

lacunar.

out of 17) and ulcerated bifurcation plaque (7 out of 17) was not statistically
different from that in patients without silent infarction;

in fact, the

ulcerations occurred on the side of the infarction in less than half of the cases.
In addition, 5 of these 17 patients had transient ischemic attacks appropriate to
the location of the infarction.

These investigators concluded that the

processes of infarction and carotid disease are most likely parallel processes
which share common risk factors, in particular, smoking and hypertension,
which were also found to be risk factors in the above studies. 16-19
To the contrary, however, a study examining the relationship between
carotid stenosis and silent cerebral infarction concluded that the more severe
the carotid stenosis, the higher the incidence of cerebral infarction ipsilateral
to the stenosis. 15

in this study, 137 out of 381 patients, or 39 percent, had

"positive CT scans."

The problem with this study, however, is its failure to

identify whether patients with TIAs (266 out of 381 patients) had infarcts in
the distribution corresponding to the TIA symptoms, for indeed it has been
noted that even with TIAs of no more than a few minutes' duration, an
appropriate infarct (cerebral infarction with transient signs) can be found on
CT scan.21 Thus the lesions in these patients may represent TIAs as opposed
to silent infarctions.

Of the 115 patients without a history of TIA, only 19

percent had positive CT scans.

Again, however, a problem arises in the

interpretation of the data, namely the failure to define the extent and
laterality of the stenoses in this 19 percent.

Thus, while this study may

suggest a causal link between carotid stenosis and cerebral infarction, further
clarification is required before meaningful conclusions can be reached.

D. Silent Cerebral Infarction and Atrial Fibrillation (Table 5)

The above studies suggest that the traditional stroke-related risk factors
of age, hypertension, cigarette smoking, and diabetes may be independently
related

to

the

development

of silent

cerebral

infarction,

while

the

relationship of carotid disease to silent infarction requires further study.
What then of the final group of patients in whom silent infarction has been
identified, namely those patients with atrial fibrillation?
1. Patients with a History of Symptomatic Stroke or TIA
The literature addressing the relationship of atrial fibrillation and
silent cerebral infarction is sparse, with only five studies specifically designed
to examine this issue. Kempster, et. al. compared 58 patients in chronic atrial
fibrillation with 168 patients in sinus rhythm;

all patients from both groups

presented with a clinically evident neurologic event.22

These investigators

discovered a statistically significant difference in the prevalence of silent
cerebral infarction between the two groups, namely 13 percent of patients
with atrial fibrillation versus 4 percent of the patients in sinus rhythm
(p<0.05).

All of the infarctions among the atrial fibrillation patients were

peripherally located, while 3 out of the 7 lucencies among patients in sinus
rhythm represented deep lacunar lesions.

The importance of this territorial

distribution relates to the fact that cardiac emboli are characteristically
associated with cortical or large subcortical strokes, while lacunar strokes are
only rarely thought to be embolic in origin.20,22-23

Thus the peripheral

location of the infarctions in the atrial fibrillation group is consistent with an
embolic source.

The higher prevalence of silent cerebral infarction in stroke

and TIA patients with atrial fibrillation corresponds to the results obtained by
Weisberg, who found silent cerebral infarctions in 18 percent of 35 post-stroke

CT scans of patients in atrial fibrillation.24 Finally, a Japanese investigative
team published an abstract of a case-control trial similar to that of Guidotti,
and found the incidence of silent infarction to be 58 percent among chronic
atrial fibrillators, 38 percent in patients with paroxysmal atrial fibrillation, and
13 percent among patients in sinus rhythm.27

However, information crucial

to evaluating this data, namely sample size and statistical significance, were
not included in the abstract.

2. Patients without Symptomatic Stroke or TIA
Three studies have examined the prevalence of silent cerebral
infarction in atrial fibrillation patients without any documented history of
stroke or TIA.

Petersen, et. al. compared 29 patients with chronic atrial

fibrillation to 29 age- and sex-matched controls.25 This study revealed that 48
percent of the chronic atrial fibrillators versus 28 percent of the controls had
evidence of silent infarction on CT scan (a nonstatistically significant
difference).

However, there was a statistically significant difference in the

number of lesions between the two groups-- 39 in the atrial fibrillation group
versus 16 in the control group.

Of note, these lesions were "mainly" cortical,

which as noted above, is a finding consistent with an embolic source.

In

another, similar study, Guidotti, et. al. compared 72 patients with chronic
atrial fibrillation against 72 age- and sex-matched controls, and found that 44
percent of the atrial fibrillation patients, versus 11 percent of the control
patients, had evidence of silent infarction on CT scan— a statistically
significant difference (p<0.05).26 Of the lesions in the atrial fibrillation group,
66 percent were subcortical, while 33 percent were cortical, as compared with
100 percent subcortical lesions in the control group.

Importantly, this study

revealed a higher (not statistically significant) prevalence of hypertension and
diabetes in the atrial fibrillation group.
Feinberg, et. al. 23 used the SPAF^ data bank, excluding patients with a
history of stroke or TIA, and determined the prevalence of silent infarctions
among 141 patients with nonvalvular atrial fibrillation;
intermittent fibrillators were included.

both chronic and

Of these 141 patients, 36 (26 percent)

had CT evidence of silent infarction; 81 percent of these 36 patients had small
deep infarcts less than one centimeter, while 36 percent had cortical or large
deep infarctions.
hypodense lesion.

Additionally, 33 percent of CT scans had greater than one
To define prevalence, this group investigated risk factors,

and noted that age and left atrial (LA) diameter significantly influenced the
prevalence of silent infarction.

In particular, in patients with LA diameter

greater than 5.0 cm and age greater than 65, the prevalence of silent infarction
was 52 percent; in patients with either one but not both of these risk factors,
the prevalence was 24 percent, while in patients with neither risk factor, the
prevalence was 11 percent.

The study did not, however, find hypertension,

diabetes, the duration of the arrhythmia, congestive heart failure, a history of
myocardial infarction, or left ventricular dysfunction statistically more
common among the atrial fibrillation patients with silent infarction,
although the investigators noted that their small sample size may have
limited their ability to detect an association.

The prevalence of silent

infarction among patients in this study with chronic atrial fibrillation was 34
percent against 22 percent in patients with intermittent atrial fibrillation.
The Feinberg study thus identified left atrial diameter and age as
positive risk factors for silent infarction among patients with atrial
fibrillation.

In light of this finding, the investigators proposed that because

the prevalence of the major stroke risk factors of hypertension and diabetes

were similar in patients with and without silent infarction, cerebrovascular
disease may not fully account for the occurrence of these infarctions.

Rather,

the positive correlation with left atrial diameter, combined with the fact that
chronic atrial fibrillation patients who generally have a greater left atrial
diameter than patients with intermittent atrial fibrillation have a greater
incidence of silent infarction than these patients, supports the idea that atrial
thrombi are responsible for these silent infarctions.

The investigators did

acknowledge, however, that the risk factor of left atrial size by itself, while
perhaps causally related to the pathophysiology of these infarctions, may also
be simply a marker of those at risk.
3. Limitations of the Five Studies of Silent Infarction in Patients with
Atrial Fibrillation
The conclusions which may be drawn from the above studies about the
relationship between atrial fibrillation and silent infarction are limited by
certain factors inherent to their design.

One problem addressed above is the

difficulty of accurately characterizing lesions as silent in the absence of regular
neurologic examinations.

The classification of lesions as silent goes to the

heart of these studies, and thus any inaccuracy in this classification necessarily
renders the interpretation of these studies and comparisons among them
problematic.

This classification difficulty arises from another feature of the

design of these studies, namely that they were all retrospective.

What is

needed then is a prospective study which follows patients with regular
neurologic histories and physical examinations, and neuroradiologic imaging
at defined intervals.

In this way, lesions identified on CT scans may be

definitively correlated with the neurologic signs and symptoms developed
among patients in the study, with the result being more accurate delineation
of lesions as silent or symptomatic, and incidence data which more closely

represents the true frequency of silent infarction in patients with atrial
fibrillation.
small;

Finally, the sample size in all of the above studies is relatively

although statistically significant results of one form or another were

obtained in most of these studies, a larger patient population would yield
more confident data on the important finding of silent infarction in the
subgroup of patients with atrial fibrillation.

E. Conclusion

Studies to date have thus demonstrated that silent cerebral infarction is
not an uncommon finding in patients with either chronic nonvalvular atrial
fibrillation or a history of a clinically evident neurologic event.

In addition,

the traditional stroke-related risk factors of age, hypertension, smoking, and
diabetes may be positively and perhaps independently related to the
development of silent infarction, although this remains unsettled.

A

number of important issues regarding silent cerebral infarction are as yet
unresolved.

In particular, the prevalence of silent infarction among the

population at large is unknown.

The mechanism of silent infarction, while

traditionally thought to be secondary to thromboemboli (a notion which is
perhaps supported by the territorial distribution of infarctions as discussed
above), has yet to be conclusively demonstrated.

Moreover, the very

important question of the impact of silent cerebral infarction on the risk of
later clinically significant events, and perhaps on the development of such
conditions as multi-infarct dementia, remains uncovered.

And finally, the

effect of warfarin prophylaxis on the incidence of silent infarction has not
been examined. If indeed silent infarction proves to be a significant risk factor
for later symptomatic disease, an argument could be made for early

anticoagulation.

Thus the delineation of subgroups at risk will be a major

advance toward the goal of protecting patients from both silent infarction and
its serious sequelae.

III. STUDY QUESTION

What is the prevalence of silent cerebral infarction among patients at
entry into the Stroke Prevention in Nonrheumatic Atrial Fibrillation Study
(SPINAF), what risk factors are associated with silent infarction, what is the
location of these infarctions, what is the incidence of silent infarction during
the course of the study, what if any is the relationship of silent infarction to
warfarin therapy and to the development of symptomatic stroke, and what
are the clinical implications of these findings?

IV. METHODS*

A. Design of the SPINAF study12

Stroke Prevention in Nonrheumatic Atrial Fibrillation (SPINAF), a
Veterans Affairs Cooperative Study, was conducted in 16 Department of
Veterans Affairs Medical Centers.

Male veterans of any age, without

echocardiographic evidence of rheumatic heart disease, who had atrial
fibrillation documented by two electrocardiograms at least four weeks apart
were considered for inclusion in the study. Baseline prothrombin times had
to be within normal range.

Aspirin and nonsteroidals were withdrawn if

* As indicated, the data analyzed herein were acquired during the SPINAF
study, which was terminated on March 1, 1991.

both physician and patient agreed.

For Arm I of the study, only patients

without clinical evidence of stroke were included.

Exclusion criteria are

summarized in Table 6.
Each center had both a blinded and an unblinded team. Patients were
randomly assigned to receive warfarin or placebo.
therapy was the maintenance of

The goal of warfarin

a prothrombin-time ratio of 1.2 to 1.5.

All

patients were followed for three years or until the termination of the study.
Patients who had a cerebral event were followed for survival.
The primary endpoint of the study was clinically evident cerebral
infarction, defined as a new neurologic deficit not attributable to dysfunction
of a single cranial nerve, the spinal cord, or the peripheral nervous system,
with persistence of the deficit or some portion thereof for longer than 12
hours and an absence of evidence of intracerebral hemorrhage or tumor on
the first cranial CT scan obtained after the onset of the deficit. The secondary
endpoints were cerebral hemorrhage and death.

B. CT Scan Acquisition and Analysis

Non-contrast CT scans were obtained from each patient at entry and
upon leaving the study.

Scans were also obtained, as indicated above, in

patients who suffered clinical strokes.

Copies of all scans were sent to the

study chairman's office at the West Haven, Connecticut, Veterans Affairs
Medical Center, where they were evaluated centrally by a committee
consisting of six neurologists and neuroradiologists.

Each scan was read by

two members of the committee, and their consensus findings were entered
into a data base. The location, size, and vascular territory of all hemorrhagic
or lucent lesions were archived.

The data base was modeled after published

NINCDS forms,28 and the territories were based on previously published
templates.29

if consensus was not reached between the two examiners, the

CT scan was arbitrated by the entire six-member committee.
Lucencies of 4.2 cm (corresponding to a diameter of 2.0 cm if they were
perfect spheres) or greater were considered to be large infarctions.2b

This

choice was based on the commonly accepted upper limit of diameter for
lacunar strokes as formulated by C. M. Fisher.30

For study purposes,

presumed strokes were divided into: a. large or small; b. subcortical (deep),
cortical (superficial), or spanning both areas; c. anterior circulation, posterior
circulation, or watershed.

The size of the stroke was estimated by recording

the maximal dimensions in millimeters in the x and y axes, then multiplying
the area thus obtained by the number of 10 mm slices (N) on which the
lucency appeared. The spherical volume was calculated by the formula

V(cm3) = (x) (y) (N) (10) (pi) / (6) (1000),
which is based on the formula for the volume of a spheroid of principal
diameters a, b, and c:

V(cm3) = (a/2) (b/2) (c/2) (4/3) (pi).

C. Other Tests
Bilateral carotid duplex studies were performed on a subset of patients
(323) entering the SPINAF trial.

In addition, transthoracic echocardiography

as well as equilibrium radionuclide angiography (ERNA) were carried out on
all patients.

D. Data Analysis
The

data

were

analyzed

at

the

Cooperative

Studies

Program

Coordinating Center in Palo Alto, California. All analyses were performed on

an intention-to-treat basis.

Baseline characteristics of patients with silent

infarctions versus patients without silent infarctions were compared using
the

Student's

t-test

for

noncontinuous variables.

continuous

variables

and

Chi-square

for

Ninety-five percent confidence intervals were

calculated for the relative risk of silent infarction using the Taylor series
approximation for the variance of the risk ratio.31

The Mantel-Haenszel

statistic^ was used to assess the effect of silent cerebral infarction at entry on
the occurrence of symptomatic stroke, combined across placebo and warfarin
groups. Scans that were obtained outside of the acceptable windows of ninety
days before and thirty days after entry, or thirty days before and ninety days
after termination (the "window criteria") were excluded from analysis.

V. RESULTS

A. Prevalence of Silent Cerebral Infarction

525 patients participated in Arm I of the SPINAF study.

Of these, 6

were missing their initial scans, and 3 had scans which did not meet the
window criteria (see METHODS, Data (section III.D)). Thus, the prevalence of
silent infarctions was based on 516 initial CT scans. Of these 516 scans, 77, or
14.9 percent, had evidence of silent cerebral infarction. 60 of these scans had 1
lesion, 12 scans had 2 lesions, 3 scans had 3 lesions, and 2 scans had 4 lesions.
Thus of the 77 positive scans, 60 (78 percent) had a single lesion, while 17 (22
percent) had multiple lesions, producing a total of 101 lesions.

B. Location and Size Distribution among the 77 Positive Scans (Table 7)

Of the 60 CT scans with single lesions, 30 (50 percent) had lesions which
were small and subcortical, 5 (8 percent) had lesions which were large and
subcortical, 3 (5 percent) had lesions which were small and cortical, and one
scan had a large, cortical lesion. Twenty lesions in this group (6 small and 14
large) spanned both the cortical and subcortical regions.
Among the 17 CT scans with multiple lesions, the majority (10/17) had
lesions which were small and subcortical or small and spanned both the
cortical and subcortical regions. The remaining lesions were a combination of
small, large, cortical, and subcortical.

C. Location and Size Distribution of the 101 Silent Infarctions

Of the 100 lesions which had specified locations (one location was
missing), 59 were subcortical, 10 were cortical, and 31 spanned both cortical
and subcortical areas.

Seventy-three (72 percent) were small, and 28 (28

percent) were large.

D. Vascular Distribution among the 77 Positive Scans (Table 8)

Of the 60 CT scans showing single lesions, 44 (73 percent) had lesions in
the distribution of the middle cerebral artery, 7 (12 percent) had lesions in the
distribution of the posterior cerebral artery, 5 (8 percent) had lesions in the
region of the cerebral watershed (spanning both the anterior and posterior
circulations), and the remaining 4 (7 percent) were distributed across the
cerebellar area of the brain.
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In the 17 scans with 41 multiple lesions, 26 (63 percent) of the lesions
were in the distribution of the middle cerebral artery, 4 (10 percent) of the
lesions were in the distribution of the posterior cerebral artery, 9 (22 percent)
of the lesions were in the region of the cerebral watershed, and 2 (5 percent) of
the lesions were in the distribution of the anterior cerebral artery.

E.

Risk Factors for Silent Cerebral Infarction among Patients at Entry with

Evidence of Silent Infarction (Table 9)

Table 9 presents a univariate comparison of the baseline characteristics
for patients with and without evidence of silent cerebral infarction upon
entry into the SPINAF study. These data suggest that age (p=0.011), a history
of hypertension (p=0.003), and active angina (p=0.012) were predictive of
silent infarction.

In addition, the mean systolic blood pressure of those

patients who had a silent stroke prior to entry was significantly higher than
that of patients who did not have evidence of silent infarction (p<0.0001). Of
note, left atrial diameter, a history of myocardial infarction, left ventricular
ejection fraction, cigarette smoking, a history of congestive heart failure,
mitral annular calcification, mitral valve prolapse, a history of diabetes, and
the documented duration of atrial fibrillation did not significantly correlate
with silent infarction.
Of the 516 patients with analyzable scans at entry, 323 had bilateral
carotid Doppler studies (Table 9).

Of the 287 patients with normal carotid

studies, 39 (13.6 percent) had evidence of silent infarction. Of the 24 patients
with abnormal but subcritical studies, 3 (12.5 percent) had evidence of silent
infarction.

Finally, of the 12 patients with critical stenosis (greater than 75

percent occlusion), 3 (25 percent) had evidence of silent infarction. However,
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while there was a trend towards increased prevalence of silent infarctions in
patients with critical carotid stenosis, it was not statistically significant.

F.

Incidence of Silent Cerebral Infarction During the Course of the Study

(Tables 10); the Effect of Warfarin

Of the 525 patients randomized in SPINAF, 307 had both an initial scan
taken at the beginning of the study and a final scan at termination to detect
silent cerebral infarction. Final scans were not available on patients who died
(37), who were terminated at their request or for administrative reasons (43),
or were lost to follow-up or otherwise could not be contacted (19). Final scans
on patients who suffered a clinical stroke (23) or hemorrhage (1) were not
performed.
event.

Scans on these patients were performed only at the time of the

Sixty-nine patients had missing scans and 26 patients had scans that

did not meet the window criteria.
Of the 307 patients who had scans at entry and termination, 40 had
scans that were abnormal at entry.

The incidence rate of silent cerebral

infarction among the 267 patients who had normal entry scans was 1.77
percent/year in the warfarin group, and 0.77 percent/year in the placebo
group.

The relative risk of silent infarction for warfarin patients was more

than twice that for placebo patients, but the 95 percent confidence interval was
very wide and overlapped 1.0.

G.

Silent Cerebral Infarction as a Risk Factor for the Development of

Symptomatic Stroke (Table 11)

During the course of the SPINAF study, 23 patients (19 in the placebo
group and 4 in the warfarin group) presented with symptomatic stroke.

Of

the 43 patients in the placebo group with evidence of silent infarction at entry,
5 (11.6 percent) developed symptomatic stroke;

of the 217 placebo-treated

patients without evidence of silent infarction at entry, 14 (6.5 percent)
developed symptomatic stroke. Of the 34 patients in the warfarin group with
evidence of silent infarction at entry, 2 (5.9 percent) developed symptomatic
stroke;

of the 222 warfarin-treated patients without evidence of silent

infarction at entry, 2 (0.9 percent) developed symptomatic stroke. Combining
the placebo and warfarin groups using the Mantel-Haenszel procedure
resulted in a p value of 0.051.

This suggests that patients with evidence of

silent cerebral infarction at entry to the SPINAF study may have been more
likely to develop symptomatic stroke than patients without evidence of silent
infarction.

VI. DISCUSSION

Major Findings of the Study
The

prevalence of silent infarction among patients in the SPINAF

study was 14.9 percent.

The majority of the lesions were small and

subcortical, involving the anterior circulation, primarily in the distribution of
the middle cerebral artery. Age, a history of hypertension, active angina, and
mean systolic blood pressure were predictive of silent infarction.

Silent

infarction, in turn, was suggestive of the development of symptomatic stroke.
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Warfarin did not appear to influence the development of silent infarction,
although the number of events occurring during the course of the study was
very small, resulting in wide 95 percent confidence limits on the relative risk
of warfarin compared to placebo.

Prevalence
The prevalence of silent infarction in this study is similar to that found
by Kempster, but is somewhat lower than in the other studies of atrial
fibrillation patients (Table 5). The 14.9 percent prevalence is, however, in the
same range as that documented among stroke, TIA, and preoperative carotid
endarterectomy patients (Table 4). The important point which emerges, even
when the lowest documented prevalence is considered, is that silent
infarction is not an uncommon finding among subgroups of patients with a
history of stroke, TIA, carotid disease, or atrial fibrillation.

Risk Factors
The predictive factors of age and hypertension in this study are in
accord with those found in the Dutch TIA study. 19

The

Feinberg23 and

NINCDS^ studies identified age but not hypertension as positive risk factors.
The Feinberg study also found left atrial diameter to be a risk factor for silent
stroke, in contradistinction to the SPINAF results.

Only the SPINAF study

identified active angina as a positive risk factor.

Location
Fifty-nine percent of the lesions in the SPINAF study were subcortical;
72 percent were small and 28 percent were large.

A higher percentage of

subcortical lesions was also identified in the Dutch TIA^, Guidotti^6/
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Feinberg23/

and carotid endarterectomy^ studies.

The Kempster^

Petersen^, and Framingham^ studies did not share this finding.

As noted

earlier, strokes resulting from cardiac emboli are characteristically associated
with cortical or large subcortical lesions, while lacunar strokes are rarely
thought to be embolic in origin.20,22-23

Nevertheless, the Feinberg study,

looking towards its identified risk factor of left atrial diameter, concluded that
atrial thrombi were responsible for the silent infarctions found in that study.
Importantly, as noted above, these investigators did not find hypertension to
be a positive risk factor.

Proposed Mechanism of Silent Infarction; The Effect of Warfarin
The SPINAF data seem to support a different mechanism for silent
stroke, namely hypertensive small vessel disease.

Consistent with this

mechanism are the high percentage of lacunar strokes documented in this
study (and in the Dutch TLA^ carotid endarterectomy^O, Guidotti^ and
indeed

Feinberg23

studies), as well as the very significant association of silent

infarction with a history of hypertension and systolic blood pressure.

It

would indeed be difficult to account for the large number of subcortical
lesions if atrial thrombi were thought to be the main culprit.

Importantly,

although the data were not statistically significant, warfarin therapy did not
influence the development of symptomatic stroke during the course of the
SPINAF study.

This of course is the expected finding if hypertensive small

vessel disease rather than atrial thrombi is the main mechanism of silent
cerebral infarction.

Incidence
The low incidence of silent infarction during this study when
compared to the prevalence of silent infarction at entry may be due to the
detailed neurological histories at entry and the intensive neurological follow¬
up during the study.

Indeed, many of the lesions identified as silent

infarctions in other studies may have been clinically evident but not
identified as such by the health care team.

In addition, there is some

definitional ambiguity in the literature as to what exactly constitutes a silent
infarction;

for example, in the Framingham

study! 6,

"silent strokes"

included only lesions unrelated to the presenting event and with no
documented clinical presentation, while in the NINCDS study!-7, both
asymptomatic lesions unrelated to the presenting event and symptomatic
unreported events unrelated to the initial presenting event but discovered on
physical examination at the time of the initial event were included.

Thus

there is difficulty in classifying an infarction as silent in the absence of regular
intensive neurologic examination.

The corollary to this observation is that

the incidence of silent infarction observed in this study may be a more
accurate reflection of the true frequency among the population of patients
with atrial fibrillation.

Relationship of Silent Infarction to the Development of Symptomatic Stroke:
Clinical Implications
Another important result of this study is the suggestion that silent
infarction is a marker for the development of symptomatic stroke.

If indeed

hypertensive small vessel disease is the main mechanism of silent infarction,
then perhaps silent stroke is truly that— in other words, subclinical disease
which shares the same etiology and mechanism as symptomatic stroke in
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most patients. This being the case, then, silent stroke and symptomatic stroke
among patients with atrial fibrillation (in whom left atrial thrombi are
thought to account for the increased risk of symptomatic stroke) may have
distinct etiologies, with hypertensive small vessel disease responsible for the
majority of silent infarctions, and left atrial thrombi the mechanism of the
majority

of

symptomatic

strokes.

From

a

therapeutic-preventative

standpoint, then, both warfarin and antihypertensive therapy would play
significant roles in the prevention of symptomatic stroke in patients with
atrial fibrillation:

Warfarin to prevent the formation of left atrial thrombi,

and antihypertensive therapy to forestall the development of small vessel
disease, which presumably causes silent infarction as well as its more serious
relative, symptomatic stroke. The next step to confirm this hypothesis would
thus be an examination of the effect of antihypertensive therapy on the
incidence of silent infarction.
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VII.

TABLES

Table 1.

Noncardiac Causes Of Ischemic Cerebrovascular
Disease
(adapted from Harrison's Principles of Internal Medicine1)

Atherosclerosis
Arteritis (e.g. temporal, granulomatous, polyarteritis, Wegener’s)
Dissections (e.g. carotid, vertebral)
Hematologic disorders (e.g. polycythemia, sickle cell disease, I I P)
Cerebral mass effect compressing intracranial arteries (e.g. tentorial herniation of
posterior cerebral artery)
Cerebral vasospasm
Reversible cerebral vasoconstriction (e.g. migraine, trauma, eclampsia)
Atherothrombotic arterial source (e.g. at bifurcation of common carotid artery)
Miscellaneous (e.g. fibromuscular dysplasia, Binswanger's disease)
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Table 2.

Causes of Cardiac Sources of Systemic Embolization
(from Cardiovascular Pharmacology and Therapeutics, Chapter

373)
Left Ventricle
Acute anterior transmural myocardial infarction
Acute inferior transmural myocardial infarction with apical involvement
Left ventricular aneurysm
Cardiomyopathy
Ventricular Tumors
Valves
Endocarditis, infective and noninfective
Prosthetic valve dysfunction
Mitral prolapse
Rheumatic heart disease
Left Atrium
Atrial fibrillation
Left atrial tumors (myxoma)
Atrial septal aneurysm
Paradoxical Complications of Cardiac Manipulation
Cardiac catheterization
Cardiac surgery
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Table 3.

Conditions Associated with Atrial Fibrillation

(from Cardiovascular Pharmacology and Therapeutics, Chapter
373)

CARDIAC
Cardiac Surgery
Cardiomyopathy
Congenital heart disease
Hypertension
Ischemic heart disease (acute or
Lipomatous hypertrophy
Pericarditis
Preexcitation syndromes
Tachybradia syndrome
Tumor
Valvular heart disease
Ventricular hypertrophy
Ventricular pacing

SYSTEMIC
Age
Alcohol
Chronic pulmonary disease
Electrocution
Electrolyte abnormalities
Hypothermia
Hypovolemia
Pregnancy
Stroke
Sudden emotional change
Thyrotoxicosis
Trauma
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Table 4.

Prevalence of Silent Cerebral Infarction (SCI)

COHORT
DEFINITION

# PATIENTS

Framingham 16

Stroke

124

10.5(13)*

1. 8 lacunar, 7 cortical;
2. glucose intolerance
found more frequently
(p<0.05) in SCI
patients.

NINCDS17

Stroke

1203

11(135)*

1. lacunar v. cortical
not documented;
2. age positively
correlated with incidence
of SCI.

Dutch TIA

TIA

2329

13(314)*

1. 79% lacunar, 14%
cortical, 7% border
zone;
2. age > 65,
hypertension and current
cigarette smoking
identified as SCI risk
factors.

381

39(137)

1. 39% lacunar, 61%
cortical cm- superficial
subcortical;
2. Classification of
lesions as silent
somewhat suspect given
failure to correlate
location of lesions with
symptomatic
distribution of TIAs.

96

18(17)*

1. 10 lacunar, 5
cortical, 1 cortical/
lacunar, 1 cerebellar.

STUDY

%(#) SILENT
INFARCTIONS

Trial19

Carotid Stenosis
Study1 ^

Carotid End¬
arterectomy
Study7®

Asymptomatic
carotid stenosis,
or TIA with or
without carotid
stenosis

Pre-operative

COMMENTS

*Silent infarction =

hypodense lesion on CT scan unrelated to presenting event and with no
documented clinical presentation

tSilent infarction =

both asymptomatic lesions unrelated to presenting event (74.9% of patients) and
sympotmatic unreported (undetected) events unrelated to initial presenting event
but discovered on physical examination at time of initial event (25.1% of
patients)
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TABLE 5.

PREVALENCE OF SILENT CEREBRAL INFARCTION (SCI)*
AMONG PATIENTS WITH ATRIAL FIBRILLATION (AF)

+/HISTORY
OF
PRIOR
STUDY

STROKE
OR TIA

% OF PATIENTS W/ SCI
AF
CONTROL
PATIENTS

COMMENTS

Kemps ter22

+

13

4

1. statistically significant difference;
2. only chronic AF patients included;
3. all lesions in AF patients “peripherally
located.”

Sasaki27

+

58, 38 (see
comment 2)

13

1. No data included in Abstract regarding
statistical significance;
2. Percents represent chronic and
paroxysmal atrial fibrillators, respectively;
3. No data as to location of lesions included
in the Abstract;
4. As neither sample size nor statistical
analysis were included in the Abstract, the
significance of these results is unclear.

Petersen25

48

28

1. difference in prevalence not statistically
significant, but statistically significant
difference in the number of lesions (39 v.
16);
2. only chronic AF patients included;
3. all lesions "mainly" cortical.

Guidotti26

44

11

1. statistically significant difference;
2. only chronic AF patients included;
3. among AF patients, 66% of lesions were
subcortical and 33% cortical, versus 100%
subcortical in the control group.

Feinberg23

26

♦Silent infarction =

1. study of 141 patients from SPAF^study;
2. left atrial diameter > 5.0cm and age > 65
positively associated with incidence of SCI;
3. both chronic and intermittent AF
patients included;
4. 81% of patients with SCI had small deep
infarcts, 36% had cortical or large deep
infarcts;
5. 33% of scans had multiple lesions.

hypodense lesion on CT scan unrelated to presenting event and with
no documented clinical presentation
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Table 6.

Exclusion of Patients with No History of Cerebral
Infarction Who were Screened for the Study12*

category
Patients screened
Patients excluded
Intermittent atrial fibrillation
Definite indication for anticoagulation or antiplatelet agents
Prosthetic heart valve
Mitral stenosis
Active thromboembolic disease
Coronary artery bypass surgery
Intracardiac thrombus
Myocardial infarction within 1 month
Contraindication to anticoagulation
Chronic alcoholism or psychological, social or general condition rendering the patient
unsuitable for anticoagulation
Coexisting medical disorder
Prothrombin time outside normal range
Hemostasis disorder
Documented peptic ulcer disease within 2 years1-, known as esophageal varices, or
history of intracranial hemorrhage
History of gastointestinal hemorrhage within 2 years1Planned surgery or invasive procedure1Laboratory abnormalities^; hematocrit < 32%; platelet count < 100,000/mm;
serum aspartate aminotransferase, serum alanine aminotransferase, or alkaline
phosphatase 2 times upper limit of normal; guaiac-positive stool; or > 5 red
cells per high-power field in urine
Uncontrolled hypertension (> 180/105 mm Hg)1Bacterial endocarditis
Atrial tumor
Inappropriate for the study (administrative criteria)
Unable or unwilling to complete follow-up
Received anticoagulation within past 6 months for more than 1 continuous month
Use of aspirin or nonsteroidal antiinflammatory agent
Echocardiogram uninterpretable
Transient ischemic episodes within 5 years
Previous cerebral infarction
Hyperthyroidism
Refused consent
Cardioversion planned
Unstable angina
Patients randomly assigned to treatment
Patients excluded after randomization
Total patients included in analysis

no.
7982
7444
1732
901
495
294
194
12
4
3
3206
2304
996
278
210
57
32
23

17
6
1
1
1605
698
477
468
334
195
31
29
23
16
5
538
13
525

*The sura of the numbers within major categories may exceed the total because some
patients were excluded for more than one reason
tReversible criterion
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Table 7. Location and Size of Silent Cerebral Infarctions*

SIZE #(%)
SMALL

LARGE

MIXED*

TOTAL

30(50)

5(8)

—

35(58)

Cortical

3(5)

1(2)

—

4(7)

Border Zone*

6(10)

14(23)

—

20(33)

Unknown

1(2)

—

—

1(2)

TOTAL

40(67)

20(33)

—

60(100)

1(6)

7(41)

LOCATION
CT Scans
with Single
Lesions

CT Scans
with
Multiple
Lesions

Subcortical

Subcortical

6(35)
1(6)

__

Border Zone*

4(24)

—

5(29)

9(53)

TOTAL

11(65)

-

6(35)

17(100)

Cortical

1(6)

>

*See METHODS (section IV) for a more detailed description of these classifications
tMixed: Both small and large lesions present in CT scans with multiple lesions
tBorder Zone: Area spanning both cortical and subcortical regions
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Table 8. Vascular Distribution of Silent Cerebral Infarctions

VASCULAR TERRITORY
Middle cerebral artery

CT Scans with Single
Lesions

44(73)

Posterior cerebral

7(12)

Cerebral watershed

5(8)

Superior cerebellar

2(3)

Anterior inferior cerebellar

1(2)

Posterior inferior cerebellar

1(2)

TOTAL

Anterior cerebral
Middle cerebral artery
CT Scans with
Multiple Lesions

#(%) OF INFARCTIONS

60(100)

1(2)
26(64)

Posterior cerebral

4(10)

Cerebral watershed

9(22)

Anterior choroidal

1(2)

TOTAL

41(100)
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Table 9.

Baseline Characteristics at Entry of Patients with
Silent Cerebral Infarction (SCI) versus Those with
Normal CT scans*

characteristic

Age (year)
Duration of documented AF
Left ventricular ejection
fraction (%)
Left atrial size (cm)
Diastolic blood pressure
Systolic blood pressure
History of hypertension
Cigarette smoking
current
discontinued within 5
years'*'
History of diabetes
Angina
History of myocardial
infarction
History of congestive heart
failure
No clinical heart disease*
Mitral regurgitation13
(0 - 1 +)
(2+ or greater)
Mitral annular calcification^
Mitral valve prolapse^
Carotid stenosis^
less than 50%
50% or greater

SCI (N=77)

NORMAL
(N=439)

69.4+6.9
7.7110.6

67.017.2
7.919.0

0.011
0.836

47.3113.3
4.810.7
82.6110.0
141.7120.1
57(73%)

47.9112.9
4.710.8
80.9110.3
132.6118.5
242(55%)

0.788
0.457
0.176

8(10%)

75(17%)

0.138

10(14%)
16(21%)
25(32%)

42(12%)
75(17%)
88(20%)

0.521
0.469
0.012

19(24%)

78(18%)

0.172

28(36%)
1(1%)

131(30%)
15(3%)

0.291
0.487
0.763

47(80%)
12(20%)
17(22%)
2(3%)

283(81%)
65(19%)
68(16%)
13(3%)

39(87%)
6(13%)

248(89%)
30(11%)

pVALUE

0.000
0.003

STATISTICALLY
SIGNIFICANT
(DENOTED X)

X

X
X

X

0.170

1.000
0.615

*AU values represent the mean ±1 standard deviation
+Based on 69 patients with SCI and 358 without
^Defined as normal left ventricular ejection fraction with no wall motion abnormality; no
left ventricular hypertrophy, valvular disease, or mitral annular calcification; and no history
of hypertension, myocardial infarction, angina, heart failure, or diabetes mellitus
nBased on 59 patients with SCI and 348 without
+Based on 77 patients with SCI and 432 without
+Based on 77 patients with SCI and 433 without
+Based on 45 patients with SCI and 278 without

Table 10.

Incidence of Silent Cerebral Infarction during the
Course of the Study*

Patient-years
Average follow-up (years)
Silent cerebral infarction

PLACEBO
(N= 127)

WARFARES'
(N=140)

261.4
2.1

282.5
2.0

2(0.77%)*

5(1.77%)*

*Follow-up for patients whose scans were normal at entry into the study
+Event rate (percent) per year

RELATTT
RISK (95%
CONFIDENCE
INTERVAL)

—

2.29
(0.52, 9.80j
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Table 11. Incidence of Symptomatic Stroke in Patients With and Without
Silent Cerebral Infarction (SCI) at Entry

PRESENCE OF SCI AT ENTRY
TREATMENT
Placebo

Warfarin

Mantel-Haenszel
statistic

Yes #(%)

No #(%)

Total

5(11.6)

14(6.5)

19

No symptomatic stroke

38(88.4)

203(93.5)

241

TOTAL

43(100)

217(100)

260

2(5.9)

2(0.9)

.4

No symptomatic stroke

32(94.1)

220(99.1)

252

TOTAL

34(100)

222(100)

256

Symptomatic stroke

Symptomatic stroke

Chi-square
3.17

p value
0.051
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